NEWS
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
Cellectis announced pre-clinical data presentation at SITC's 39th Annual Meeting, showcasing strategies to enhance CAR T-cell efficacy against solid tumors. The research focuses on overcoming challenges in the tumor microenvironment (TME) using TALEN®-mediated gene editing to generate allogeneic CAR T-cells. The company developed two key approaches: a FAP-dependent expression system to limit cytotoxic activity to tumor areas, and integration of IL-12 into PD-1 regulatory elements while inactivating TGFBR2. These strategies showed enhanced T-cell proliferation and infiltration while reducing tumor burden and limiting side effects, potentially offering new therapeutic options for solid tumor patients.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2554Followers
107Following
28KVisitors
Follow